Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Impact of Mutational Burden and IPSS-M on Response to ESAs in Lower Risk Myelodysplastic Neoplasms

Blood (2023) 142 (Supplement 1): 4595.

https://doi.org/10.1182/blood-2023-189053

Published: 2023

Journal Articles

AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network

Blood (2022) 140 (Supplement 1): 6279–6281.

https://doi.org/10.1182/blood-2022-169696

Published: 2022

Journal Articles

DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation

Blood (2022) 140 (Supplement 1): 215–216.

https://doi.org/10.1182/blood-2022-164584

Published: 2022

Journal Articles

Rare PNH Cells May be Considered As Genuine PNH Clone: Insights from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Magali Le Garff-Tavernier, Jean-Philippe Vial, Thomas Boyer, Nicolas Chapuis, Véronique Harrivel, Anne-Catherine Lhoumeau, Elsa Bera, Isabelle Kittler, Marie Loosveld, Gerard Socie, Régis Peffault de Latour, Bernard Drenou, Agathe Debliquis, Orianne Wagner-Ballon

Blood (2022) 140 (Supplement 1): 8645–8647.

https://doi.org/10.1182/blood-2022-160207

Published: 2022

Journal Articles

Immunocluster: A Computational Tool to Explore the Immune Profile and Cellular Heterogeneity of Hematological Diseases Using Liquid and Imaging Mass, and Flow Cytometry Data

Jessica A. Timms, James W Opzoomer, Kevin Blighe, PhD, Benedetta Apollonio, PhD, Thanos Mourikis, Nicolas Chapuis, PharmD, PhD, Richard Bekoe, Alan G. Ramsay, BSc,MSc,PhD, Donal P. McLornan, MRCP, PhD FRCPath, Claire Harrison, DM, FRCP, FRCPath, Paul R. Barber, Peter Parker, Michaela Fontenay, MD PhD, James N. Arnold, Shahram Kordasti, MD PhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-140258

Published: 2020

Journal Articles

Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models

Blood (2019) 134 (Supplement_1): 2671.

https://doi.org/10.1182/blood-2019-123418

Published: 2019

Journal Articles

Too big for flow

Carole Almire, Nicolas Chapuis

Blood (2019) 134 (6): 576.

https://doi.org/10.1182/blood.2019001172

Published: 2019

Journal Articles

Multicentric MFI30 Study: Standardization of CD30 Expression By Flow Cytometry in Non-Hodgkin Lymphoma

Agathe Pruvot Debliquis, pharmD, Lucile Baseggio, MD, Marie-Christine Jacob, Sabrina Bouyer, Franck Genevieve, MD PhD, Julien Guy, MD, Caroline Mayeur-Rousse, MD, Nicolas Chapuis, PharmD, PhD, Hind Bennani, Thomas Matthes, MD, Bernard Drenou

Blood (2018) 132 (Supplement 1): 2869.

https://doi.org/10.1182/blood-2018-99-115990

Published: 2018

Journal Articles

A pernicious mean corpuscular volume

Alexa S. Green, Nicolas Chapuis

Blood (2018) 131 (4): 472.

https://doi.org/10.1182/blood-2017-09-807149

Published: 2018

Journal Articles

Multicentric Validation of the "Monocyte Assay" for Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry

Sihem Tarfi, Véronique Harrivel, MD, Florent Dumezy, MD, Julien Guy, MD, Mikael Roussel, MD PhD, Aguirre Mimoun, MD, Pierre Fenaux, MD PhD, Nicolas Chapuis, PharmD, PhD, Éric Solary, MD PhD, Dorothée Selimoglu-Buet, PhD, Orianne Wagner Ballon

Blood (2017) 130 (Supplement 1): 4273.

https://doi.org/10.1182/blood.V130.Suppl_1.4273.4273

Published: 2017

Journal Articles

Lenalidomide-Mediated Erythroid Improvement in Non-Del(5q) Myelodysplastic Syndromes Is Associated with Bone Marrow Immuno-Remodeling

Gwenneg Kerdivel, PhD, Virginie Chesnais, PhD, Etienne Becht, PhD, Andrea Toma, MD PhD, Nicolas Cagnard, PhD, Florent Dumont, PhD, Alice Rousseau, Pierre Fenaux, MD PhD, Sylvie Chevret, MD PhD, Nicolas Chapuis, PharmD, PhD, Valentina Boeva, PhD, Wolf-Herman Fridman, Olivier Kosmider, Michaela Fontenay, MD PhD

Blood (2017) 130 (Supplement 1): 2983.

https://doi.org/10.1182/blood.V130.Suppl_1.2983.2983

Published: 2017

Journal Articles

Dyserythropoiesis Evaluated By Red Score and Hepcidin/Ferritin Levels Predicts Response to Epoetin Zeta in Lower Risk MDS

Blood (2017) 130 (Supplement 1): 1705.

https://doi.org/10.1182/blood.V130.Suppl_1.1705.1705

Published: 2017

Journal Articles

Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes

Virginie Chesnais, Marie-Laure Arcangeli, Caroline Delette, Alice Rousseau, Hélène Guermouche, Carine Lefevre, Sabrina Bondu, M’boyba Diop, Meyling Cheok, Nicolas Chapuis, Laurence Legros, Sophie Raynaud, Lise Willems, Didier Bouscary, Evelyne Lauret, Olivier A. Bernard, Olivier Kosmider, Françoise Pflumio, Michaela Fontenay

Blood (2017) 129 (4): 484–496.

https://doi.org/10.1182/blood-2016-03-707745

Published: 2017

Includes: Supplemental data

Journal Articles

Plasma cell leukemia revealing a G6PD deficiency

Anna Raimbault, Nicolas Chapuis

Blood (2016) 128 (26): 3178.

https://doi.org/10.1182/blood-2016-08-736322

Published: 2016

Journal Articles

Architectural and Functional Heterogeneity of Hematopoietic Stem/Progenitor Cells in Non-Del(5q) Myelodysplastic Syndromes

Virginie Chesnais, Marie-laure Arcangeli, PhD, Caroline Delette, Alice Rousseau, M'boyba Khadija Diop, Andrea Lefevre, Meyling H. Cheok, MSPharm, PhD, Nicolas Chapuis, PharmD, PhD, Laurence Legros, MD PhD, Sophie Raynaud, MD, Lise Willems, MD PhD, Didier Bouscary, MD PhD, Evelyne Lauret, PhD, Olivier A. Bernard, PhD, Olivier Kosmider, MD PhD, Francoise Pflumio, PhD, Michaela Fontenay, MD PhD

Blood (2016) 128 (22): 3153.

https://doi.org/10.1182/blood.V128.22.3153.3153

Published: 2016

Journal Articles

Clonal B-Cell Lymphocytosis with Marginal Zone Features and Splenic Marginal Zone Lymphoma Share a Similar Cytogenetic and Mutational Profile

Paul Legendre, MD, Olivier Kosmider, PharmD, PhD, Coralie Derrieux, PharmD, Nicolas Chapuis, PharmD, PhD, Isabelle Radford-Weiss, PharmD, Hélène Guermouche, Barbara Burroni, MD, Julie Bruneau, MD PhD, Bénédicte Deau, MD, Richard Delarue, MD, Olivier Hermine, MD PhD, Didier Bouscary, MD PhD, David Sibon, MD PhD

Blood (2016) 128 (22): 2962.

https://doi.org/10.1182/blood.V128.22.2962.2962

Published: 2016

Journal Articles

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition

Blood (2015) 126 (11): 1346–1356.

https://doi.org/10.1182/blood-2015-01-621870

Published: 2015

Includes: Supplemental data

Journal Articles

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia

Blood (2013) 122 (20): 3521–3532.

https://doi.org/10.1182/blood-2013-03-493163

Published: 2013

Includes: Supplemental data

Journal Articles

Targeted Therapy in CMML: Complete Molecular Response to Sorafenib in a Patient with a FLT3-ITD Malignant Hematopoiesis

Olivier Kosmider, MD, PhD, Nicolas Chapuis, Sophie Kaltenbach, Romain Coriat, Pascaline boudou-Rouquette, Lise Willems, Virginie Chesnais, Isabelle Radford-Weiss, Valérie Bardet, Patrick Mayeux, Jerome Tamburini, Michaela Fontenay, MD, PhD, Didier Bouscary

Blood (2012) 120 (21): 4786.

https://doi.org/10.1182/blood.V120.21.4786.4786

Published: 2012

Journal Articles

RAD001: A Clinico-Biological Phase I GOELAMS trial of Everolimus Association with High Dose Chemotherapy in Late Relapsing AML Patients Under 65 Years of Age

Sophie Park, Nicolas Chapuis, Franck Saint Marcoux, PharmD, PhD, Christian Recher, MD, PhD, Norbert Vey, MD, Thomas Prebet, MD, PhD, Patrice Chevallier, MD, Jean-Yves Cahn, MD, Arnaud Pigneux, MD, PhD, Bruno Lioure, Francis Witz, MD, Thierry Lamy, MD, PhD, Annabelle Merlat, Roselyne Delepine, Francois Dreyfus, Marie-christine Béné, Norbert Ifrah, Didier Bouscary, MD, PhD

Blood (2011) 118 (21): 945.

https://doi.org/10.1182/blood.V118.21.945.945

Published: 2011

NARROW

Impact of Mutational Burden and IPSS-M on Response to ESAs in Lower Risk Myelodysplastic Neoplasms

AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network

DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation

Rare PNH Cells May be Considered As Genuine PNH Clone: Insights from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Immunocluster: A Computational Tool to Explore the Immune Profile and Cellular Heterogeneity of Hematological Diseases Using Liquid and Imaging Mass, and Flow Cytometry Data

Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models

Too big for flow

Multicentric MFI30 Study: Standardization of CD30 Expression By Flow Cytometry in Non-Hodgkin Lymphoma

A pernicious mean corpuscular volume

Multicentric Validation of the "Monocyte Assay" for Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry

Lenalidomide-Mediated Erythroid Improvement in Non-Del(5q) Myelodysplastic Syndromes Is Associated with Bone Marrow Immuno-Remodeling

Dyserythropoiesis Evaluated By Red Score and Hepcidin/Ferritin Levels Predicts Response to Epoetin Zeta in Lower Risk MDS

Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes

Plasma cell leukemia revealing a G6PD deficiency

Architectural and Functional Heterogeneity of Hematopoietic Stem/Progenitor Cells in Non-Del(5q) Myelodysplastic Syndromes

Clonal B-Cell Lymphocytosis with Marginal Zone Features and Splenic Marginal Zone Lymphoma Share a Similar Cytogenetic and Mutational Profile

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia

Targeted Therapy in CMML: Complete Molecular Response to Sorafenib in a Patient with a FLT3-ITD Malignant Hematopoiesis

RAD001: A Clinico-Biological Phase I GOELAMS trial of Everolimus Association with High Dose Chemotherapy in Late Relapsing AML Patients Under 65 Years of Age

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only